pharmaceutical industry

GSK to withdraw blood cancer drug from US after trial failure

Reuters
GSK to withdraw blood cancer drug from US after trial failure

GSK. The GlaxoSmithKline logo is displayed in this illustration taken January 17, 2022.

Dado Ruvic/Reuters

GSK's blood cancer drug Blenrep fails the main goal of a late-stage study designed to show it was better than an existing treatment in the market

British drugmaker GSK said on Tuesday, November 22, it has initiated a process to withdraw the US approval for its blood cancer drug Blenrep, after the therapy failed to meet the requirements of a key trial.

Earlier this month, the company said Blenrep had failed the main goal of a late-stage study designed to show it was better than an existing treatment in the market, stoking fears that regulatory approval may be rescinded by authorities.

The drug was given an accelerated approval by the U.S. regulator in 2020 for patients with relapsed or refractory multiple myeloma. Last year, the drug garnered 89 million pounds ($105.4 million) in global sales. – Rappler.com

Add a comment

Sort by

There are no comments yet. Add your comment to start the conversation.